GBS - GBS pops 7% on plans for COVID-19 antibody trials following validation study

GBS (NASDAQ:GBS) gains 7.4% premarket after announcing that it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study. The objective of this study was to develop a diagnostic test to detect SARS-CoV-2 IgG in human plasma. The statistical design of the study was powered in accordance with this study objective. Preliminary findings were: The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using positive and negative SARS CoV-2 human plasma samples. The time in obtaining results was less than 10 minutes. Following the above findings, the company is planning to commence clinical saliva SARS-CoV-2 Antibody trials, with the objective of submitting an Emergency Use Authorization request to the U.S. FDA.

For further details see:

GBS pops 7% on plans for COVID-19 antibody trials following validation study